Expert Analysis

Expert Analysis: Prognosis and Prediction

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Expert Analysis: Prognosis and Prediction

Faculty:

Matthew Ellis, MD, PhD
Daniel F. Hayes, MD
Hope S. Rugo, MD

CME CREDIT INFORMATION

Release Date: 02/21/08

Expiration Date: 02/20/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the use of genetic signatures in determining benefit from therapy for patients with breast cancer
Cite the significance of genetic polymorphisms on metabolism of therapeutic agents used in the treatment of breast cancer
Describe prognostic markers used to predict outcomes in patients with breast cancer

Topics covered include:

Recurrence Score Predictive of Adjuvant Therapy Benefit in Node-Positive, ER-Positive Breast Cancer
RS Prognostic in Hormone Receptor–Positive Operable Breast Cancer
Impact of Cytochrome P450 2D6 Polymorphisms on Tamoxifen Metabolism
Ki-67 Labeling Index as a Prognostic Marker for Adjuvant Endocrine Therapy
Development of a Predictive Model of Endocrine Response
Combination Index of Gene Copy Number Alterations and Expression Signature in Node-Negative Breast Cancer
70-Gene Profile and Outcomes in Node-Positive Breast Cancer
Evaluating Correlation of Outcomes With Polysomy 17 Following Anthracycline and Trastuzumab Treatment
HER2 Assessment Methods and Outcomes in the HERA Trial
Sensitive Molecular Assay for Detecting Lymph Node Metastases
Molecular Subtype Defines Efficacy of Anthracyclines in Adjuvant Therapy for Breast Cancer
Concluding Remarks

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.